Lupin, one of the leading pharmaceutical companies in India, announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its calcium acetate capsules, 667 mg having received final approval from the United States Food and Drug Administration (FDA).

Lupin's calcium acetate capsules, 667 mg are the AB rated generic equivalent of Fresenius Medical Care North America's (Fresenius) PhosLo Gelcaps 667 mg and are indicated for the control of hyperphosphatemia in end stage renal failure.

PhosLo Gelcaps had annual US sales of USD 54.5 million, the company said.

Shares of the company declined Rs 28.45, or 1.37%, to trade at Rs 2051 at the BSE (Monday).